...
首页> 外文期刊>Current medical research and opinion >Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants
【24h】

Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants

机译:用新型口腔抗凝血剂对心房颤动患者缺血性卒中,重大出血和深静脉血栓形成的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: Our study examined the impact of adherence to novel oral anticoagulants [NOACs - dabigatran and rivaroxaban] on ischemic-stroke (IS), major-bleeding (MB), deep-vein-thrombosis and pulmonary-embolism (DVTPE) risk in a large, nationwide, propensity-matched sample.Methods: A retrospective cohort study utilized data from a US commercial managed-care database (2010-2012). Adult patients with 1 diagnosis of atrial fibrillation/flutter (ICD-9 427.31/32), 1 prescription of NOACs and CHA(2)DS(2)-VASc score 1 were included. Patients were categorized as adherent versus nonadherent (using proportion of days covered [PDC 80%]) based on their NOAC use up to 6 months and those continued its use up to 12 months. The patients were matched using propensity score (based on inverse probability treatment weighting) and the risk of IS, MB, DVTPE outcomes was evaluated for the matched cohorts' post-adherence (exposure) assessment using multivariable Cox regression.Results: A total of 3,629 and 1,946 patients with at least 6 and 12 months of NOAC use were included. Based on a PDC threshold of 80%, adherence rates at 6 and 12 month usage were 77% and 76%, respectively. Patients with lowest adherence were from the South, had low stroke risk and EPO/HMO insurance. Using Cox models with matched cohorts, nonadherence within the first 6 months' use was significantly associated with higher risk of IS and DVTPE (IS: hazard ratio [HR]=1.82, p=.002; DVTPE: HR=2.12, p=.010) and the risk increased with nonadherence for the prolonged period of 12 months' use (IS: HR=2.08, p=.022; DVTPE: HR=5.39, p=.003). The risk of MB was not different (p.05) between adherent and nonadherent groups for both 6 month and 12 month cohorts.Conclusion: Adherence to NOACs for both 6 months and prolonged use (up to 12 months) was associated with a reduction in IS and DVTPE risk, but did not substantially increase risk of MB. Further studies on newer, individual NOACs and older populations are warranted.
机译:目的:我们的研究检测了依从性对新的口腔抗凝血剂[Noacs - Dabigatran和Rivaroxaban]对缺血性 - 中风(是),主要出血(MB),深静脉血栓形成和肺栓塞(DVTPE)风险的影响大,全国范围内,匹配匹配的样本。方法:回顾性队列研究使用来自美国商业管理保险数据库的数据(2010-2012)。 1患者1诊断心房颤动/颤动(ICD-9 427.31/32),& 1张巨乳和CHA(2)DS(2)-vasc评分1的处方。患者被归类为粘附而非粘附(使用[PDC 80%]的比例),基于其Noac使用长达6个月,那些持续超过12个月的时间。使用倾向评分(基于反概率处理加权)匹配患者,使用多变量COX回归评估匹配的群组后依赖性(暴露)评估的风险,MB,DVTPE结果。结果:总共3,629还包括1,946名患有至少6和12个月的Noac使用的患者。基于80%的PDC阈值,分别为6%和12个月的粘附率分别为77%和76%。依靠最低的患者来自南方,卒中风险低,欧洲运动会和欧洲央行/清新保险。使用具有匹配队列的Cox模型,前6个月内的非正常使用与较高的IS和DVTPE风险显着相关(是:危险比[HR] = 1.82,P = .002; DVTPE:HR = 2.12,P =。 010),风险增加了不正常的12个月使用时间(是:HR = 2.08,P = .022; DVTPE:HR = 5.39,P = .003)。在6个月和12个月的粘附剂和非较为群体之间的粘附和非闭合组之间的风险并不不同(P>在粘附组群之间)。结论:遵守巨乳的6个月,长期使用(最多12个月)与减少有关IN和DVTPE风险,但没有大幅增加MB的风险。有权进一步研究较新的,个别诺布斯和较老的人口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号